Recap: Hologic Q3 Earnings

Loading...
Loading...

Shares of Hologic HOLX were unchanged in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 19.05% over the past year to $0.75, which beat the estimate of $0.37.

Revenue of $822,900,000 decreased by 3.46% year over year, which beat the estimate of $607,710,000.

Outlook

Q4 EPS expected between $0.95 and $1.15.

Q4 revenue expected between $925,000,000 and $1,025,000,000.

Details Of The Call

Date: Jul 29, 2020

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/e9eoejo2

Technicals

Company's 52-week high was at $63.60

52-week low: $26.49

Price action over last quarter: Up 38.70%

Company Profile

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: breast health (44% of sales), diagnostics (39%) surgical (14%), and skeletal health (3%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (74%), followed by Europe (12%), Asia (9%), and other international markets (5%). Hologic is headquartered in Bedford, Massachusetts.

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: Earnings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...